Next-Generation RET Inhibitor

LOXO-260

Phase 1

Enrolling
Lung Cancer, Medullary Thyroid Cancer, or Other Advanced Solid Tumors
LOXO-260

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.